MBX Biosciences is trading at $47.00, down 4.08% in pre-market, with no clear company-specific announcement explaining the decline. - On October 13, MBX Biosciences fell 5.81% to $49.00; coverage noted healthcare-sector context but did not establish a catalyst for the further drop. - A recent Stifel price-target increase was positive, not a direct explanation for this move. - Major indices were mixed, so broad-market direction does not clearly account for the decline.